Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma.

Front Oncol · 2022 · PMC9869613 · PMID 36698400

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Some biomarkers with a clear trend should be interpreted with caution.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.